Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Arrowhead Pharmaceuticals (ARWR)

Arrowhead Pharmaceuticals posts $30.8 million net income on $264.0 million revenue

Positive Impact 3 of 5 earnings Written later

Arrowhead reported fiscal 2026 first-quarter results for the period ended December 31, 2025, with revenue of $264.0 million, up from $2.5 million a year earlier. The company swung to net income attributable to Arrowhead of $30.8 million, or $0.22 per diluted share, from a loss of $173.1 million, or $1.39 per share, in the prior-year quarter.

Key points

  • Revenue was $264.0 million for the quarter ended December 31, 2025, compared with $2.5 million for the same quarter a year earlier.
  • Net income attributable to Arrowhead was $30.8 million, or $0.22 per diluted share, compared with a loss of $173.1 million, or $1.39 per share.
  • The company closed two concurrent public offerings with gross proceeds totaling $930 million and received a $200 million upfront payment from Novartis.

The filing

CompanyArrowhead Pharmaceuticals (ARWR)
Form8-K, current report
Filed with the SECFeb 5, 2026, 4:05 PM ET
Accession number0000879407-26-000033

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 1:17 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on February 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.